Anticoagulants Effect on the platelets Rich Plasma Growth Factors Levels

Authors
Dr Hoda Elhady Ahmed Abdelmoneim*, Dr Ahmed Salah Abdalhaleem
General Organization of Teaching Hospitals and Institutes
*Corresponding Author
Hoda Elhady Ahmed Abdelmoneim
Egypt, Zkazik City, 4 Alhasn Bn Alhaithm Street, Alqaumia
Email: hodaelhady1@gmail.com, 00201140026110

Abstract
Background: Platelet-rich plasma (PRP) are platelets concentrates made of autogenous blood with a high number of platelets in a small volume of plasma. The main component that appears to be associated with the therapeutic effect in PRP is the presence of growth factors (GF). Variable techniques for PRP preparation produce variable amounts of growth factors.

Subjects and Methods: The study included a total number of 30 healthy males volunteer. We collected blood samples on lithium heparin, EDTA (ethylene diamine tetra acetic acid) and trisodium citrate as anticoagulants and counted platelets in whole blood and PRP which were prepared by single spin and double spin. We measured platelets derived growth factor-BB (PDGF-BB) and transforming growth factor beta-1(TGFB-1) in PRP and platelets poor plasma (PPP).

Results: We obtained high significant difference between PRP and PPP were prepared from samples on the different anticoagulants (p<0.01) for both TGFB-1 and PDGF-BB. No significant correlation between platelets counts and both TGFB-1 and PDGF-BB in PRP from the different anticoagulants samples (p>0.05). High significant difference was found between growth factors in the PRP were prepared by single spin and double spin (p<0.01) where TGFB-1 and PDGF-BB were higher in single spin PRP than that prepared by double spin.

Keywords: Anticoagulants, Platelets rich plasma, Growth factors.

Introduction
Platelets are small fragments of megakaryocytes, have important role in clot formation, inflammation and immune response. Platelets contain growth factors in their alpha granules, such as transforming growth factor-beta (TGF-b), fibroblast growth factor-2 (FGF-2), platelet-derived growth factors (PDGF), which are thought to produce beneficial effects on the healing process. The ultimate goal of platelet-rich plasma treatment is to concentrate these growth factors and reintroduce them to a site of injury[1]. Platelet-rich plasma (PRP) is a generic term referring to any sample of autologous plasma with platelets concentrations above baseline blood values. The platelets growth factors content are quite variable among individuals and it is not necessarily proportional to the platelets count. Activation and release of growth factors also occur during platelets processing. Hence, the sole platelets count cannot be predictive of the growth factors content in individual PRP preparations. Platelets are extremely sensitive to any kind of process induced stress, from blood
extraction to PRP gel production. Thus the amount of platelet derived factors available at the end of the manipulation process depends on cumulative effects over platelets, starting from phlebotomy and ending with gel formation\(^2\). PRP is safe and is free from transmissible diseases such as HIV and hepatitis and delivers high concentrations of growth factors to the surgical area. These are native growth factors in their biologically determined ratios. This is what distinguishes PRP from recombinant growth factors\(^3\). Variability in the cellular composition of platelet-rich plasma preparations can create methodological challenges for investigators\(^4\).

**Aim of the work**

Evaluation the effects of anticoagulants and both single and double spin on the platelets rich plasma levels of platelets derived growth factor-BB (PDGF-BB) and transforming growth factor beta-1 (TGFB-1).

**Subjects and Methods**

This study included 30 healthy males volunteer their age ranged from 18 to 48 years, those volunteers have no relevant diseases and free of any drugs known to affect platelets functions for 7 days before the study. To maintain platelets integrity, we used lithium heparin, EDTA (ethylene diamine tetra acetic acid) and trisodium citrate as anticoagulants. We draw 9 milliliters (mls) blood from each person where they divided into 4 mls were added on tube contains lithium heparin (17 IU/ml), 3 mls blood on K2 EDTA, the concentration of K2EDTA is 1.5±0.25 mg/ml blood and 1.8 mls blood on 0.2 ml trisodium citrate concentration, 32.0 g/l Na3C6H5O7.2H2O. For every person we prepared: Three PRP were obtained by single spin, three PRP were obtained by double spin and three PPP (from samples were collected on lithium heparin, EDTA and trisodium citrate). For all samples on the different anticoagulants and PRP were obtained by single and double spin we made complete blood counts on Sysmex kx21- Roche diagnostic- for platelets counts. For all prepared PRP and PPP samples we measured TGFB-1 and PDGF-BB by an enzyme linked immunosorbent assay (ELISA).

**Method:** Single spin separation was made by centrifugation for all samples for 8 minutes at 1000 rpm under constant temperature conditions, the whole blood was separated into three layers: The upper layer is plasma which is consists of two layers; the upper is PPP, and the lower is PRP, the intermediate layer is rich in WBCs and the bottom layer is consisting mostly of RBCs. We collected PPP and preserve at -20 for growth factors quantification and platelets were counted in PRP, then PRP is divided into two tubes; one of them centrifuged at 3500 rpm for 15 minutes under similar temperature conditions and again platelets counts was made from the pellet. the first tube and the collected pellet from the second tube undergo gel formation by addition of CaCl2 (5%) by percent 20% from the whole PPP and PRP (were obtained by single and double spin). After a firm clot formation, the samples were centrifuged for 5 minutes at 3200 rpm and the supernatant was frozen at -20 for growth factors quantification by ELISA.

**Growth factors quantification:** Quantification of TGFB-1\(^5\) and PDGFBB\(^6\) by ELISA technique using Assypro LLC reagents from affymetrix eBioscience, Bender MedSystems GmbH, Vienna (Austria). The assay employs quantitative sandwich immunoassay technique. The growth factors levels were determined using the ELISA assay method. All kits were tested according to the manufacturer’s instructions. In general, the test procedure included adding standards and samples to a microplate precoated with an antibody against each growth factor. Any growth factor present was bound by the immobilized receptor, after any unbound substances were rinsed away, an enzyme-linked polyclonal antibody specific for each growth factor was added to the wells. After a second wash, a substrate solution was added, and color developed in proportion to the amount of bound growth factor in the first step. The color development was stopped, and the intensity of the color was measured using ELISA reader.
Statistical analysis; mean, standard deviation, ANOVA, least significant difference (LSD), paired t test and correlation studies were performed using SPSS software version 14 (SPSS Inc, Chicago, ILL Company).

Results
This study was conducted on 30 healthy males of matched age. TGFB1 mean using single spin method in heparinized PRP was (152.03±31.26) and PPP was (20.46±6.8), EDTA PRP was (80.9±17.8) and PPP was (17.7±5.45), sodium citrate PRP was (77.13±23.4) and PPP was (17.5±10.15). ANOVA denoted that there was a highly significant difference between groups (p<0.01), table (1), figure (1). LSD showed high significant value for TGFB1 between heparinized samples and all other anticoagulants (p<0.01) while there was a non-significant difference (p>0.05) between TGFB1 was measured in EDTA and trisodium citrate samples PRP, table (2).

Regarding PDGFBB using single spin method; ANOVA showed that there was a highly significant difference (p<0.01) between all PRP and PPP, mean of heparinized PRP was (25.73±7.09) and (1.8200±1.416) for PPP, EDTA PRP was (17.70±3.706) and (1.407±0.912) for PPP and trisodium citrate PRP was (13.83±3.374) and (1.355±1.05) for PPP, table (3), Figure (2). LSD for PDGFBB denoting high significant difference between all PRP from the different anticoagulants (p<0.01), table (4).

Pearson correlations between platelets counts and both TGFB1 and PDGFBB in PRP collected on the different anticoagulant denoting no significant difference between all anticoagulants (p>0.05), table (5) and (6) respectively. The comparison between single and double spin methods for PRP separation by paired t test for both TGFB1 and PDGFBB revealed high significant difference between single and double spin methods for all the different anticoagulants (p<0.01), table (7) and (8) respectively.

Table (1): Simple analysis of variance (ANOVA) for TGFB1; mean, standard deviation (SD), F and P value

|              | Heparin PRP | Edta PRP | Citrate PRP | Heparin PPP | Edta PPP | Citrate PPP |
|--------------|-------------|----------|-------------|-------------|----------|-------------|
| TGFB1 (ng/ml)| Single spin | Single spin | Single spin | Single spin | Single spin | Single spin |
| Mean         | 152.03      | 80.90    | 77.13       | 20.46       | 17.73    | 17.53       |
| SD±          | ±31.26      | 17.88±   | 23.42±      | ±6.80       | ±5.45    | ±10.15      |
| F            | 181.4       | < 0.01** |             |             |         |             |
| P            |             | < 0.01** |             |             |         |             |

P<0.01 (Highly Significant) = **

Table (2): Least significance difference (LSD) for TGFB1 in the different anticoagulants

|              | Heparin TGFB1 PRP (ng/ml) | Edta TGFB1 PRP (ng/ml) | Citrate TGFB1 PRP (ng/ml) | Heparin TGFB1 PPP (ng/ml) | Edta TGFB1 PPP (ng/ml) |
|--------------|---------------------------|------------------------|---------------------------|---------------------------|------------------------|
| Edta, TGFB1  | <0.01**                   | -                      | -                         | -                         | -                      |
| Citrate, TGFB1 | <0.01**                  | >0.05^                 | -                         | -                         | -                      |
| Heparin, TGFB1 (ng/ml) | <0.01**              | <0.01**                 | <0.01**                   | -                         | -                      |
| Edta, TGFB1 (ng/ml) | <0.01**              | <0.01**                 | <0.01**                   | <0.01**                   | -                      |
| Citrate, TGFB1 (ng/ml) | <0.01**              | <0.01**                 | <0.01**                   | <0.01**                   | >0.05^                 |

P>0.05 (Non Significant) = ^
P<0.01 (Highly Significant) = **
**Table (3):** Simple analysis of variance (ANOVA) for PDGFBB; mean, standard deviation (SD), F and P value

|                | Heparin PRP | Edta PRP | Citrate PRP | Heparin PPP | Edta PPP | Citrate PPP |
|----------------|-------------|----------|-------------|-------------|----------|-------------|
|                | Single spin PDGFBB (Pg/ml) | Single spin PDGFBB (Pg/ml) | Single spin PDGFBB (Pg/ml) | Single spin PDGFBB (Pg/ml) | Single spin PDGFBB (Pg/ml) |
| Mean           | 25.7333     | 17.7000  | 13.8333     | 1.8200      | 1.407    | 1.355       |
| SD ±           | ± 7.09      | 3.706±   | 3.374±      | ± 1.416±    | ± 0.912± | ± 1.05±     |
| F              | 236.4       |          |             |             |          |             |
| P              | <0.01**     |          |             |             |          |             |

P < 0.01 (Highly Significant) = **

**Table (4):** Least significance difference (LSD) for PDGFBB of the different anticoagulants

|                | Heparin PDGFBB (Pg/ml) | Edta PDGFBB (Pg/ml) | Citrate PDGFBB (Pg/ml) | Heparin PDGFBB (Pg/ml) | Edta PDGFBB (Pg/ml) |
|----------------|------------------------|---------------------|------------------------|------------------------|---------------------|
|                | PRP                    | PRP                 | PRP                    | PPP                    | PPP                 |
| Edta, PDGFBB (Pg/ml) | PRP                  | <0.01**             | -                      | -                      | -                   |
| Citrate, PDGFBB (Pg/ml) | PRP             | <0.01**             | <0.01**                | -                      | -                   |
| Heparin PDGFBB (Pg/ml) | PPP                 | <0.01**             | <0.01**                | <0.01**                | >0.05^              |
| Edta, PDGFBB (Pg/ml) | PPP                 | <0.01**             | <0.01**                | <0.01**                | >0.05^              |
| Citrate, PDGFBB (Pg/ml) | PPP             | <0.01**             | <0.01**                | <0.01**                | >0.05^              |

P > 0.05 (Non Significant) = ^
P < 0.01 (Highly Significant) = **

**Table (5):** Pearson correlations between platelets counts and TGFB1 in PRP collected on the different anticoagulant

|                    | TGFB1 in PRP on heparin | TGFB1 in PRP EDTA | TGFB1 in PRP trisodium citrate |
|--------------------|--------------------------|-------------------|-------------------------------|
| Platelets counts   | 0.316                    | -0.182            | 0.119                         |
| R                  | >0.05^                   | >0.05^            | >0.05^                        |

P > 0.05 (Non Significant) = ^

**Table (6):** Pearson correlations between platelets counts and PDGFBB in PRP collected on the different anticoagulant

|                    | PDGFBB in PRP on heparin | PDGFBB in PRP EDTA | PDGFBB in PRP trisodium citrate |
|--------------------|--------------------------|-------------------|---------------------------------|
| Platelets counts   | -0.067                   | -0.221            | 0.346                           |
| R                  | >0.05^                   | >0.05^            | >0.05^                          |

P > 0.05 (Non Significant) = ^

**Table (7):** Paired t test for TGFB1 first and second spin

|                    | Single Spin mean±SD | Double Spin mean±SD | Paired t test | P   |
|--------------------|---------------------|---------------------|---------------|-----|
| TGFB1 (ng/ml)      | Lithium heparin     | 152.03±31.26        | 131.03±33.35  | 5.213 | <0.01** |
| TGFB1 (ng/ml)      | Edta                | 80.90±17.88         | 63.26±17.57   | 8.116 | <0.01** |
| TGFB1 (ng/ml)      | Trisodium citrate   | 77.13±23.42         | 65.60±19.95   | 4.44  | <0.01** |

P < 0.01 (Highly Significant) = **
Table (8): Paired t test for PDGFBB first and second spin

|                | Single Spin mean±SD | Double Spin mean±SD | Paired t test | P    |
|----------------|---------------------|---------------------|---------------|------|
| PDGFBB (pg/ml) |                     |                     |               |      |
| Lithium heparin| 25.73±7.09          | 21.83±3.98          | 3.135         | <0.01**|
| PDGFBB (pg/ml) |                     |                     |               |      |
| Edta           | 17.7±3.7            | 15.46±4.19          | 4.489         | <0.01**|
| PDGFBB (pg/ml) |                     |                     |               |      |
| Trisodium citrate| 13.83±3.37      | 12.23±2.84          | 2.876         | <0.01**|

P<0.01 (Highly Significant) = **

Figure (1): Mean of TGFB1 (ng/ml) were collected by single spin.

![Figure 1](image)

1=Heparinized PRP, 2= EDTA PRP, 3=Trisodium citrate PRP, 4=Heparinized PPP, 5=EDTA PPP, 6= Trisodium citrate PPP.

Figure (2): Mean of PDGFBB (pg/ml) were collected by single spin

![Figure 2](image)

1= Heparinized PRP, 2= EDTA PRP, 3=Trisodium citrate PRP, 4=Heparinized PPP, 5=EDTA PPP, 6= Trisodium citrate PPP.

Discussion

Platelets, an important reservoir of growth factors in the body, play an important role in many processes such as coagulation, immune response, angiogenesis and the healing of damaged tissues. Numerous proteins are contained in the platelets granules. High concentrations of growth factors, in a form of sterile mass that can be used immediately for clinical
purposes. The clinical use of PRP for a wide variety of applications has been reported in oral and maxillo-facial surgery, orthopedic surgery, treatment of soft tissue diseases and injuries, treatment of burns, tissue engineering and implantology. PRP has been utilized and studied since the 1970s and used clinically in humans for its healing properties, and this attributed to the increased concentrations of growth factors and secretory proteins that may enhance the healing process on a cellular level. The hope is that PRP enhances the recruitment, proliferation, and differentiation of cells involved in tissue regeneration. Therefore PRP is a concentrate with the ‘right’ factors in the ‘right’ proportions necessary for the healing process. However, many protocols available induce high methodology variability.

In our study we found platelets counts mean in heparinized, EDTA and trisodium citrate (after addition 10% which is the dilution factor) samples were 238.16±59, 246 ± 31 and 249± 42 (x10^3 cells/µl) increased to 726±181, 734±190 and 740±176 (x10^3 cells/µl) in PRP respectively when collected by single spin and with no significant difference between groups (p>0.05). While platelets counts increased in the second spin to 923±156, 946±166 and 972±163 (x10^3 cells/µl) in Lithium heparin, EDTA and trisodium citrate samples PRP but also with no significant difference between different anticoagulants. Higher results for platelets counts were obtained by Queiroz da Silva et al., where they found the mean of platelets concentration in PRP was 1622 x 10^3 cells/µl, which represents 5.3 folds higher than the basal number (303 x 10^3 cells/µl). Cho et al., reported that the platelets amount should be three to seven times higher than the basal value.

We found in our study a single spin centrifugation of 1000 rpm for 8 minutes yields higher growth factors level in PRP than levels were obtained by double spin although higher platelets counts were obtained in the double spin. This can be explained by deterioration of the platelets function due to excessive centrifugation. These results are consistent with Landesberg et al., where they evaluated the effect of different centrifugation forces and showed that > 800-g spin may reduce the amount of growth factor released by PRP.

Interestingly, in our study no significant correlation between either TGFβ1 or PDGFβB and platelets counts in PRP samples were obtained from sample collected on heparin, EDTA or trisodium citrate (p>0.05), tables (5) & (6) respectively. These results is consistent with observations reported by Weibrich et al., which indicating that the platelet count may not be a sufficient marker to predict biological activity, while Bausset O. et al., reported that correlation between platelets counts and growth factors release could be observed for PDGF-AB, but not for TGF-B1.

In our study TGFβ-1 in heparinized sample was higher than that in samples collected on EDTA and trisodium citrate with high significant difference (p<0.01), table (2). These results are consistent with Bocci V. et al., and Valacchi G. et al., where they reported that the release of growth factors from platelets take place more efficiently in presence of heparin when they utilized heparin normally used for therapeutic purposes and ACD (Citric acid, Na citrate, Glucose) for isolation of PRP.

The actual challenge for PRP optimization is to determine the main bioactive components responsible for the clinical effects. We should not consider the platelet itself nor its growth factors, but certainly the synergy of both. Thus, the capacity of the preparation method to preserve maximal amount of resting and activable platelets may be a specific advantage. In our study we activate platelets in PRP by CaCl2 for gel formation and growth factors release which gave results consistently with Bausset O. et al., where they found that the method for PRP preparation proposed in their study allows high levels of PDGF-AB, and TGF-β1 release after platelets activation by CaCl2 and glass tubes. Notably, these results were obtained with a lower centrifugation speed presumed to ensure better platelets functionality. In addition, it has been demonstrated that platelets activation in presence of heparin, is significantly produce high amount of PDGF and TGF-β1 in heparinized PRP samples, in
contrast with the procedure that use ACD[14]. Moreover, numerous extracellular proteins, growth factors, chemokines, cytokines, enzymes, lipoproteins, involved in a variety of biological processes, interact with heparin and/or heparin sulfate at the cell surface and in the extracellular matrix. The interaction of some important growth factors derived from platelets, as the Fibroblast growth factor (FGF) with its receptor: Fibroblast growth factor receptor (FGFR), is more efficient in presence of heparin[16]. The heparin-binding protein site near to the FGFR regulates the angiogenesis, then the presence of heparin induce an enhancement of the mitogenic activity of FGF[17].

In our study LSD shows no significance difference between TGFB-1 was measured in sample collected on EDTA and trisodium citrate (p>0.05), table (2), similar results were obtained by Ronaldo JF et al., where they could not find differences in TGFβ-1 and VEGF concentration among the EDTA and citrate anticoagulants and explained that by similar platelets concentration between groups[18]. Fukaya M et al., considered heparin treated platelets more easily discharge α-granules, which contains PDGF than ACD-A–treated ones as they found the concentration of PDGF decreases in ACD-A while increases in heparin[19], which is consistent with our findings where we found PDGF-BB was the highest in PRP were prepared from heparinized samples than EDTA or citrate samples, with high significant difference between groups (p <0.01), table (3).

We agree with Jing Qiao et al., that we need more data to find the proper therapeutic doses for platelets concentrates suitable for different clinical applications [20].

Source of grants: General Organization for Teaching Hospitals and Institutes

References

1. Foster TE, Puskas BL, Mandelbaum BR, Gerhardt MB et Rodeo SA: Platelet-rich plasma: from basic science to clinical applications. Am J Sports Med. 2009:37: 2259-72.

2. Mazzucco L, Balbo V, Cattana E, Guaschino R et Borzini P: Not every PRP-gel is born equal. Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet®, RegenPRP-Kit ®, Plateltex ® and one manual procedure. International Society of Blood Transfusion 2009:97:110-118.

3. Marx RE: Platelet-Rich Plasma (PRP): What is PRP and what is not PRP? Implant Dentistry 2009; Vol.10 no,4, 225-228.

4. Bhatia A, Ramya BS, Dayananda SB et Panchakshari BK: Comparison of different methods of centrifugation for preparation of platelet-rich plasma (PRP). Indian Journal of Pathology and Oncology 2016: October-December ;3(4);535-39.

5. Andrae J, Gallini R et Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008: 22(10):1276-1312.

6. Lee JW, Kwon OH, Kim TK, Cho YK, Choi KY, Chung HO, Cho BC, Yang JD et Shin JH: Platelet-rich plasma: quantitative assessment of growth factor levels and comparative analysis of activated and inactivated groups. Arch Plast Surg. 2013:40:530-35.

7. Lubkowska A, Dolegowska B et Banfi G: Growth factor content in PRP and their applicability in medicine: Journal of biological regulators & Homeostatic. 2012: vol. 26, no.2 (S) 3-22.

8. Queiroz da Silva L, Huber SC, Montalvão SA, Bassora FD, Vinicius De Paula E et Annichino-Bizzacchi J: Platelet Activation is not crucial for platelet-rich plasma (PRP), when used as autologous therapeutic product, and could be lyophilized without any growth factor loss. Blood 2016:128:2639.

9. Cho JM, Lee YH, Baek RM, et Lee SW: Effect of platelet-rich plasma on ultraviolet b-induced skin wrinkles in nude mice. J
10. Landesberg R, Roy M et Glickman RS: Quantification of growth factor levels using a simplified method of platelet rich plasma gel preparation. J Oral Maxillofac Surg. 2000:58:297-300.

11. Weibrich G, Kleis WK, Hafner G et Hitzler WE: Growth factor levels in platelet-rich plasma and correlations with donor age, sex, and platelet count. J Craniomaxillofac Surg. 2002:30:97-102.

12. Bauusot O, Girau do L, Veran J, Magalon J, Coudreuse J, Magalon G, Dubois C, Serratrice N, Dignat-George F et Sabatier F: Formulation and Storage of Platelet-Rich Plasma Homemade Product. BioResearch Open Access 2012: Vol. 1, no. 3, 115-123.

13. Bocci V, Valacchi, G, Rossi, R, Giustarini D, Paccagnini E, Pucci AM et Di Simplicio P: Studies on the biological effects of ozone: 9. Effects of ozone on human platelets. Platelets 1999:10,110-116.

14. Valacchi G et Bocci V: Studies on the biological effects of ozone: 10. Release of factors from ozonated human platelets. Mediators Inflamm. 1999:8,205-209.

15. Anitua E, Sanchez M, Zalduendo MM, Dolors de la Fuente M, Prado R, Orive G et Andía I: Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009: 42:162-170.

16. Weibrich G, Kleis WK, Hafner G, Hitzler WE et Wagner W: Comparison of platelet, leukocyte, and growth factor levels in point-of-care platelet-enriched plasma, prepared using a modified curasan kit, with preparations received from a local blood bank. Clin Oral Implants Res. 2003:14:357-362.

17. Peysselon F et Ricard-Blum S: Heparin-protein interactions: From affinity and kinetics to biological roles. Application to an interaction network regulating angiogenesis. Matrix biology: journal of the International Society for Matrix Biology 2014:35, April,73-81.

18. Ronaldo JF, Silva NP, Haddad NF, Lopes LS, Ferreira FD, Filho RB, Cappelletti PA, Mello W, Cordeiro-Spinetti E et Balduino A: Platelet-rich Plasma obtained with different anticoagulants and their effect on platelet numbers and mesenchymal stromal cells behavior In Vitro: Stem Cells International 2016: Vol. 3, January,1-11.

19. Fukaya M et Ito A: A New Economic Method for Preparing Platelet-rich Plasma: Plast Reconstr Surg Glob Open. 2014: June, Vol. 2, Issue 6, p e162.

20. Qiao J, An N et Ouyang X: Quantification of growth factors in different platelets concentrates. Platelets. 2017: Vol.28, Issue 8, 774-778.